AZN
Astrazeneca plc
$186.85-1.14%
Setup
Watch
Buy Zone
$185-$194.25
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
45
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
AZN chart
Loading chart…
ADX
Weak or Absent19.5Long Term
Down ↓Intermediate Term
Down ↓Short Term
Down ↓Overall Quality45
RS Rating
53
relative strength
Fundamentals
70
Solid fund-Q
Volume Demand
68
+51% vs avg
Technical Setup
63
5/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
Avoid
Entry
$185
Entry Zone
$185-$194.25
Stop / Risk
$170.2
RS Rating
53
Volume confirmed
No
Targets
$222 / $231.25
Breakout · IBD Setup
3 ✓ 5 ✗
Entry $185–$194.25Stop $170.2Target $222 / $231.25
Market regimeRange
Quality45
RS Rating53
Above 50-MA+12.54%
Above 200-MA+3.76%
VolumeWeak
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
45
MarketRange
SetupWatch
ConfidenceExperimental · not backtested
Fund-Q70 · Solid
StatusAvoid
Stock Data
52-Week Range153 – 213
Price % Chg YTD6.47%
Price % Chg 4wk16.69%
50-Day Avg Vol3.2 Mil
P/E Ratio26.4
Market Cap$289B
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)23.13%
Sales % Chg (Qtr)6.7%
EPS Growth 5y22.05%
Sales Growth 5y16.31%
Annual ROE22.6%
Gross Margin74.11%
Operating Margin23.31%
Net Margin17.68%
Debt / Equity0.66
Setup levels
Current price
$186.85
Pivot
$185
Distance to buy
-12.2%
52-week range
153.41-212.72
Trigger evidence
No active trigger evidence available.
Pattern levels: near highs
Financial health checks
5/5
Return on equity above 15%
ROE 22.6%
Net margin above 10%
Net margin 17.68%
EPS growing quarter on quarter
EPS q/q 23.13%
Sales growing quarter on quarter
Sales q/q 6.7%
Debt to equity below 1.0
D/E 0.66
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE22.6%
vs sector +0.0%
Net margin17.68%
vs sector +0.0%
Gross margin74.11%
vs sector +6.9%
EPS growth q/q23.13%
vs sector +15.5%
Sales growth q/q6.7%
vs sector -12.0%
Debt / equity0.66
vs sector +0.01
Business quality
70
GradeSolid
EPS rating57
P/E26.4
Market cap$289B
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-11-05
Trigger date
—
Days on list
1
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.